James A. Joyce
Founder and Chief Executive Officer
Mr. Joyce has 20 years of public market CEO and corporate board leadership experience. As founder of Aethlon Medical, he has overseen the development of the Aethlon Hemopurifier® from theoretical concept to being named a “Breakthrough Device” by the United States Food and Drug Administration. The Hemopurifier® (a Time Magazine “Top 25 Invention” and “Remarkable Advance in Healthcare”) reduces the circulating presence of life-threatening viruses and cancer-promoting exosomes as a therapeutic strategy to address two significant unmet needs in global health.
Mr. Joyce is also the founder and Executive Chairman of Exosome Sciences, Inc., a biomarker discovery company that is majority owned by Aethlon Medical.
On behalf of Aethlon Medical and Exosome Sciences, Mr. Joyce has established collaborations with leading government and non-government research institutes worldwide. He is the co-author of peer-reviewed journal publications and the co-inventor of patents both issued and pending. Under his leadership, Aethlon has been awarded government contracts from the National Cancer Institute and the Defense Advanced Research Projects Agency (DARPA), a United States Department of Defense agency. Mr. Joyce has also testified before Congress and worked on Capitol Hill to advance medical device and biodefense industry legislation.
Prior to founding Aethlon Medical, Mr. Joyce was Managing Director at James Joyce & Associates, founder and CEO of Mission Labs Inc., Principal at London Zurich Securities, Inc., and a member of the Denver Broncos Football Club of the National Football League. Mr. Joyce is a graduate of the University of Maryland.
James B. Frakes
Chief Financial Officer and Senior Vice President – Finance
Mr. Frakes joined Aethlon Medical in January 2008. He has 27 years of CFO level financial responsibility for publicly traded companies, as well as, specific knowledge and experience in equity (IPO, follow-on public offerings and private placements) and debt transactions, acquisitions, public reporting and Sarbanes-Oxley section 404 internal control requirements.
Mr. Frakes received an MBA from the University of Southern California, and completed his BA with Honors at Stanford University.
Michael has an extensive and diverse background in medical device product development and process improvement. His previous research has led to multiple publications in various peer-reviewed journals from Elsevier and the Royal Society of Chemistry. Michael holds a Bachelor’s degree in Biology and a Master’s degree in Biomedical Engineering from the University of Texas at Dallas.
Annette Marleau, PhD
Director of Research
An expert in immunology, virology, and cell biology who formerly held academic research positions at the The Scripps Research Institute (La Jolla, CA) and the University of Nebraska Medical Center (Omaha, NE). Dr. Marleau holds a Bachelor’s degree in Biomedical Sciences from the University of Waterloo, a Master’s degree in Reproductive Immunology from the Ontario Veterinary College at the University of Guelph, and a PhD in Immunology from the University of Western Ontario in Canada.
Rodney S. Kenley
Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and VP of Electronic Drug Infusion. During this tenure he conceived of and managed the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.
Mr. Kenley founded Aksys Ltd. in January 1991 to develop and commercialize his concept of a daily home hemodialysis system which was commercially launched in 2002 as the PHD system. In 2004, Mr. Kenley initiated the development of a second-generation home hemodialysis system in partnership with DEKA Research & Development Corporation in Manchester, New Hampshire. In 2007, the assets of Aksys Ltd. were acquired by DEKA, where Mr. Kenley was employed prior to joining Aethlon.
Mr. Kenley is the recipient of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at the Kellogg School of Management at Northwestern University and at other business schools in the area of entrepreneurship.
Mr. Kenley received his Bachelor of Arts degree in Biology and Chemistry from Wabash College, a Masters of Science degree in Molecular Biology from Northwestern University and a Masters of Management from the Kellogg School of Management, also at Northwestern University.